Searchable abstracts of presentations at key conferences in oncology

oa0001p050 | (1) | PacRim7

Preclinical development of CDDD3-14, a potent and selective inhibitor of CDK4/6 for the treatment of breast cancer

Bantie Laychiluh , Tadesse Solomon , Likisa Jimma , Yu Mingfeng , Noll Benjamin , Heinemann Gary , Milne Robert , Albrecht Hugo , Wang Shudong

Deregulation of the CDK4/6-cyclin D-Rb-E2F pathway is common in subtypes (e.g. ER+/HER2−) of breast cancer, and activation/amplification of cyclin D1 (CCND1) and CDK4/6, or deletion/mutation of CDKN2A gene that encodes p16INK4a are the major mechanisms. Aberration in the upstream pathways such as PI3K/Akt/mTOR can also lead to the deregulation of the CDK4/6 axis, which drives carcinogenesis and development of resistance to therapies. Therefore, inhibition of CDK4/6 is a ...

oa0001p027 | (1) | PacRim7

Estrogen maintains mammographic density via heparanase mediated induction of SDC-1 and -4

Huang Xuan , Blick Tony , Lloyd Thomas , Ferro Vito , Hickey Theresa , Tilley Wayne , Haupt Larisa , Thompson #Erik W , Hugo #Honor J

Mammographic density (MD) is an independent risk factor for breast cancer, however what molecule or pathway within MD tissue contributes to this risk? High MD is characterized by an abundance of connective tissue stroma which is rich in heparan sulfate proteoglycans (HSPGs). Of these, SDC1 and SDC4 are upregulated in breast cancer, and we have observed a significantly higher abundance of these proteins in high vs low MD pair-wise comparisons from breast tissue from 8 individua...